NO963497L - Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel - Google Patents

Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel

Info

Publication number
NO963497L
NO963497L NO963497A NO963497A NO963497L NO 963497 L NO963497 L NO 963497L NO 963497 A NO963497 A NO 963497A NO 963497 A NO963497 A NO 963497A NO 963497 L NO963497 L NO 963497L
Authority
NO
Norway
Prior art keywords
fibrin
specific antibody
antithrombotic agent
methods
antithrombotic
Prior art date
Application number
NO963497A
Other languages
English (en)
Other versions
NO963497D0 (no
Inventor
Paul Edward Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of NO963497D0 publication Critical patent/NO963497D0/no
Publication of NO963497L publication Critical patent/NO963497L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fremgangsmåte for anvendelse av et fibrin-spesifikt antistoff for in vivo inhibisjon av trombedannelse, samt farmasøytiske sammensetninger og sett for anvendelse i slike fremgangsmåter er beskrevet.
NO963497A 1994-02-24 1996-08-22 Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel NO963497L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (2)

Publication Number Publication Date
NO963497D0 NO963497D0 (no) 1996-08-22
NO963497L true NO963497L (no) 1996-10-16

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963497A NO963497L (no) 1994-02-24 1996-08-22 Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel

Country Status (26)

Country Link
US (1) US5487892A (no)
EP (1) EP0749320A4 (no)
JP (1) JPH09509429A (no)
KR (1) KR970701063A (no)
CN (1) CN1146157A (no)
AU (1) AU708897B2 (no)
BG (1) BG62476B1 (no)
BR (1) BR9506949A (no)
CA (1) CA2183953A1 (no)
CZ (1) CZ246496A3 (no)
FI (1) FI963288A0 (no)
GE (1) GEP20002257B (no)
HU (1) HUT76536A (no)
LT (1) LT4192B (no)
LV (1) LV11784B (no)
MD (1) MD1521G2 (no)
MX (1) MX9603602A (no)
NO (1) NO963497L (no)
NZ (1) NZ281481A (no)
PL (1) PL316005A1 (no)
RU (1) RU2152801C2 (no)
SG (1) SG53279A1 (no)
SK (1) SK108496A3 (no)
TJ (1) TJ301B (no)
UA (1) UA41984C2 (no)
WO (1) WO1995022986A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US7829294B2 (en) * 2004-12-28 2010-11-09 Daiichi Pure Chemicals Co., Ltd. Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP3586874A1 (en) 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
WO1988001514A1 (en) * 1986-08-25 1988-03-10 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
EP0710720A1 (en) * 1988-06-13 1996-05-08 American Biogenetic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
US5487892A (en) 1996-01-30
BR9506949A (pt) 1997-09-23
MD960334A (en) 1997-09-30
BG100863A (en) 1997-08-29
CA2183953A1 (en) 1995-08-31
RU2152801C2 (ru) 2000-07-20
FI963288A (fi) 1996-08-23
UA41984C2 (uk) 2001-10-15
SK108496A3 (en) 1997-10-08
EP0749320A1 (en) 1996-12-27
HUT76536A (en) 1997-09-29
GEP20002257B (en) 2000-10-25
JPH09509429A (ja) 1997-09-22
WO1995022986A1 (en) 1995-08-31
EP0749320A4 (en) 1997-06-18
MD1521F2 (en) 2000-08-31
AU708897B2 (en) 1999-08-12
LV11784B (en) 1997-12-20
CN1146157A (zh) 1997-03-26
AU1843495A (en) 1995-09-11
HU9602337D0 (en) 1996-10-28
LT4192B (en) 1997-07-25
NO963497D0 (no) 1996-08-22
SG53279A1 (en) 1998-09-28
MX9603602A (es) 1997-05-31
PL316005A1 (en) 1996-12-23
KR970701063A (ko) 1997-03-17
FI963288A0 (fi) 1996-08-23
MD1521G2 (ro) 2001-03-31
LT96140A (en) 1997-03-25
NZ281481A (en) 1998-07-28
BG62476B1 (bg) 1999-12-30
LV11784A (lv) 1997-06-20
CZ246496A3 (en) 1997-04-16
TJ301B (en) 2001-08-06

Similar Documents

Publication Publication Date Title
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
NO963497L (no) Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel
ATE133179T1 (de) Steroid-sulfatase-inhibitoren
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NO944764L (no) Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
FI103111B1 (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten valmistamiseksi
NO980178D0 (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
GEP20084346B (en) Protein kinase c inhibitors
IL139144A0 (en) Mycobacterial inhibitors
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
WO1996031119A3 (de) Organische peroxoverbindungen enthaltendes mittel zur instrumentendesinfektion
ID28174A (id) Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya
AU5994696A (en) Modified alpha-d-glcp-(1-2)-alpha-d-glcp-(1-3)-alpha-d-glcp- analogues
DK0828483T3 (da) Anvendelse af tropolonderivater som inhibitorer af enzymet inositolmonophosphatase
NO924280L (no) Mellomprodukter ved dannelse av calicheamicin og esperamicin oligosaccharider
AU5269696A (en) Anellated beta-carbolines
GR1001368B (el) Φαρμακευτικοί φορείς.
DK0477178T3 (da) Terapeutisk middel og kit til behandlingen af rheumatoid polyartritis
ES1028515Y (es) Replica de implantes dentales.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application